Treatment Options for Elevated P-tau 217 Levels in Alzheimer's Disease

Understanding P-tau 217 as a Biomarker

Plasma p-tau217 levels are significantly elevated in Alzheimer's disease compared to non-AD neurodegenerative diseases, with the largest increases observed in p-tau217 specifically 2
P-tau217 levels correlate with both amyloid-β plaques and tau tangles in the brain, making it a reliable indicator of AD pathology 3
The diagnostic performance of plasma p-tau217 is comparable to CSF biomarkers and tau-PET imaging in memory clinic settings 4
P-tau217 can accurately predict future cognitive decline and conversion to AD dementia in patients with mild cognitive impairment (MCI) 5

Anti-amyloid antibody therapies like donanemab and aducanumab should be considered as first-line treatments for patients with elevated P-tau 217 levels, as they have been shown to reduce plasma p-tau217 levels, which correlates with improved clinical outcomes 1

Serial measurements of plasma p-tau217 can be used to monitor disease progression and treatment response, with longitudinal increases in p-tau217 correlating with worsening cognition and brain atrophy 1

The FDA has granted Breakthrough Device designation to a p-tau181 assay as an aid in diagnostic evaluation of AD, with additional tests for p-tau217 in clinical development 1

Not all p-tau assays have equivalent performance; clinicians should use high-performing immunochemical assays with validated clinical utility 4
Factors that may influence p-tau217 levels include cerebrovascular and cardiovascular diseases, requiring careful interpretation in patients with these comorbidities 5
The relationship between plasma p-tau217 and specific tau pathologies is still being elucidated 3
Current research priorities include establishing factors influencing biological, pre-analytical, and analytical variation in p-tau217 measurements 1